Moderna Covid Vaccine: Fewer Breakthrough Cases, Higher Myocarditis Rates In Young Men

Moderna Covid Vaccine: Fewer Breakthrough Cases, Higher Myocarditis Rates In Young Men

The coronavirus vaccines continue to make headlines these days. Now, it’s Moderna’s turn, and below, you can check out the latest reports about the novel vaccines that are triggering massive debates all over the world regarding their efficiency vs. potential side effects.

More experts have been saying that vaccines are the only solution to end the pandemic.

Moderna covid vaccine efficiency 

CNBC revealed that Moderna defended the use of its Covid-19 vaccine Thursday, saying the protection it offers against severe disease, hospitalization, and death outweighs the risk of myocarditis.


As you probably know by now, this is a rare heart condition seen in a small number of young men who received the shot.

The company announced last week that the FDA needed more time to decide whether to authorize its two-dose vaccine for use in children ages 12 to 17. The agency has been looking into reports of myocarditis or the inflammation of the heart muscle.

CNBC notes the following:

“Reported cases of the rare heart inflammation in men under age 30 are relatively higher after Moderna’s vaccine compared with those who received the shots made by Pfizer and BioNTech, Moderna Chief Medical Officer Dr. Paul Burton told reporters on a call Thursday.”

He also said:

“While I think health authorities are carefully assessing the data, being appropriately cautious, you can see that they continue to recommend the use of the mRNA-1273 Moderna vaccine.”

He continued and said the following on the call:

“We believe that the balance of benefit and risk is extremely positive,” he added.

Pfizer vaccine in the news again

Earlier today, we revealed that Pfizer makes headlines again after some new data involving allegedly poor practices at a contract research company helping to carry out Pfizer’s covid vaccine trial raise questions about the data integrity and the regulatory oversight.

The article says that The BMJ notes that researchers who were testing Pfizer’s vaccine at a few sites in Texas during that autumn, speed may have come at the cost of “data integrity and patient safety.”

Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.